HLS Therapeutics (TSX:HLS) Beginning Cash Position : C$29.72 Mil (As of Mar. 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Beginning Cash Position?

HLS Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was C$29.72 Mil.

HLS Therapeutics's quarterly Beginning Cash Position increased from Sep. 2023 (C$28.32 Mil) to Dec. 2023 (C$29.26 Mil) and increased from Dec. 2023 (C$29.26 Mil) to Mar. 2024 (C$29.72 Mil).

HLS Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (C$26.38 Mil) to Dec. 2022 (C$28.77 Mil) but then declined from Dec. 2022 (C$28.77 Mil) to Dec. 2023 (C$27.80 Mil).

HLS Therapeutics Beginning Cash Position Historical Data

The historical data trend for HLS Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Beginning Cash Position Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

14.39

60.30

26.38

28.77

27.80

HLS Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															28.36	28.18	28.32	29.26	29.72

HLS Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

HLS Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (TSX:HLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

Executives

Polar Asset Management Partners Inc.

10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines